Peyronie's disease: experience of local treatment with Orgotein.
22 patients with Peyronie's disease have been treated with Orgotein, the new anti-inflammatory metalloprotein which pronounced superoxide dismutase activity patients with long-standing and severe symptoms were selected for the trial. The drug was given monthly by injection into the indurated areas of penis. In 19 patients, where the sexual act could be performed with difficulties or the penile angulation made intercourse impossible, marked improvement was seen or normal function was restored. No adverse reactions by Orgotein were seen.
D000328:Adult; D000368:Aged; D003075:Coitus; D004341:Drug Evaluation; D006801:Humans; D007267:Injections; D008297:Male; D008667:Metalloproteins / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy* / Q000503:physiopathology; D010413:Penis / Q000503:physiopathology
D008667:Metalloproteins; C005180:orgotein